0001104659-15-052491.txt : 20150722 0001104659-15-052491.hdr.sgml : 20150722 20150722152344 ACCESSION NUMBER: 0001104659-15-052491 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150731 FILED AS OF DATE: 20150722 DATE AS OF CHANGE: 20150722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Forward Pharma A/S CENTRAL INDEX KEY: 0001604924 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36686 FILM NUMBER: 15999920 BUSINESS ADDRESS: STREET 1: ?STERGADE 24A, 1 CITY: COPENHAGEN STATE: G7 ZIP: 1100 BUSINESS PHONE: 0114533444242 MAIL ADDRESS: STREET 1: ?STERGADE 24A, 1 CITY: COPENHAGEN STATE: G7 ZIP: 1100 6-K 1 a15-16039_16k.htm 6-K

Table of Contents

 

 

 

FORM 6-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the month of July 2015

 

Commission File Number: 001-36686

 

Forward Pharma A/S

 

Østergade 24A, 1

1100 Copenhagen K, Denmark

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F   x

Form 40-F  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).

 

Yes  o

No  x

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).

 

Yes  o

No  x

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  o

No  x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  N/A

 

 

 


Table of Contents

 

This Report of Foreign Private Issuer on Form 6-K contains information regarding the results of the extraordinary general meeting of shareholders of Forward Pharma A/S (the “Company”) held on July 20, 2015.

 

Table of Contents

 

Item 1. Results of Extraordinary General Meeting

3

 

 

Signatures

4

 

2


Table of Contents

 

Item 1.  Results of Annual Meeting

 

On July 22, 2015 the Company announced on its website (http://www.forward-pharma.com) the results of the extraordinary general meeting of its shareholders held on July 20, 2015 at the Company’s offices, Østergade 24A, 1, 1100 Copenhagen K, Denmark (the “Extraordinary General Meeting”). DKK 3,412,904.20 of the Company’s share capital and 34,129,042 votes, respectively, were present or represented at the Extraordinary General Meeting.

 

The following actions were taken at the Extraordinary General Meeting:

 

1.              Election of Jakob Mosegaard Larsen by 32,473,545 votes in favour, and with 1,655,497 votes against.

 

2.              Election of Grant Hellier Lawrence by 34,129,042 votes in favour, and with 0 votes against.

 

3.              Authorization of the chairman of the general meeting to file the election of additional members of the board of directors to the Danish Business Authority and in this connection to make any such amendments and supplements to the application and the resolution that may be appropriate or required as a condition for registration by 34,129,042 votes in favour, and with 0 votes against.

 

3


Table of Contents

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

FORWARD PHARMA A/S

 

 

 

 

Date: July 22, 2015

By:

/s/ Joel Sendek

 

 

Joel Sendek

 

 

Chief Financial Officer

 

4